Catena Biosciences
CatenaBio is a biotechnology company focused on developing next-generation protein conjugation technologies for novel therapeutics, especially in oncology. Their proprietary CysTyr® platform enables the fusion of biomolecules in any structure or orientation, allowing for the creation of multi-payload conjugates with unprecedented flexibility, stability, and therapeutic potential. The company's mission is to revolutionize antibody-drug conjugates (ADCs) by enabling the attachment of multiple payloads of any size and complexity to a single antibody, leading to improved efficacy and safety in cancer treatment.
Industries
Nr. of Employees
small (1-50)
Catena Biosciences
Berkeley, California, United States, North America
Products
Multi-payload antibody-drug conjugate program (preclinical lead targeting TROP2)
A preclinical antibody-drug conjugate program employing site-specific multi-payload conjugation (flexible DAR configurations) targeting TROP2, reported to show improved efficacy and tolerability in preclinical tumor models.
Multi-payload antibody-drug conjugate program (preclinical lead targeting TROP2)
A preclinical antibody-drug conjugate program employing site-specific multi-payload conjugation (flexible DAR configurations) targeting TROP2, reported to show improved efficacy and tolerability in preclinical tumor models.
Services
Conjugation platform partnerships and R&D collaborations
Collaborative programs to apply site-specific bioconjugation chemistry to partner assets, enabling multi-payload conjugates and novel biotherapeutic constructs.
Conjugation platform partnerships and R&D collaborations
Collaborative programs to apply site-specific bioconjugation chemistry to partner assets, enabling multi-payload conjugates and novel biotherapeutic constructs.
Expertise Areas
- Protein bioconjugation chemistry
- Antibody-drug conjugate (ADC) design
- Engineered enzyme development for site-specific coupling
- Preclinical oncology model evaluation
Key Technologies
- Enzyme-catalyzed tyrosine–cysteine coupling
- Site-specific bioconjugation
- Antibody-drug conjugates (ADCs)
- Cleavable linker chemistry